FDA removes Boxed Warning for testosterone products after TRAVERSE trial benefits Lipocine

Lipocine Inc.

FDA removes Boxed Warning on cardiovascular risk for all testosterone products based on TRAVERSE trial.
Label changes include adding TRAVERSE results and retaining Limitation of Use for age-related hypogonadism.
FDA requires product-specific blood pressure information from ABPM studies on all testosterone labels.
Lipocine CEO says label changes beneficial to approved TLANDO and pipeline candidates for obesity and liver disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.